Navigation Links
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Date:6/3/2009

biparsciences.com.

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applica
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
2. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
3. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
4. Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
5. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
6. Premier Research Announces Milestone Investigational New Drug Application
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
9. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
10. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
11. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... from the Company,s Board of Directors in order to ... of Impax in 1995 and served as the Company,s ... April 2014. Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO ... Chief Executive Officer stated, "We wish to thank Larry ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Rochester Medical Corporation (NASDAQ: ROCM ) will announce ... 2012.  The Company will then hold a quarterly conference call ... 3:30 p.m. central time (4:30 p.m. eastern time). ... be accessed at Rochester Medical,s website at www.rocm.com .  ...
...   Hospira, Inc. (NYSE: HSP ), the ... announced enrollment of the first patient in a Phase III ... III program, which follows a successful Phase I trial that ... EPO and the reference product, Amgen,s Epogen ® in ...
Cached Medicine Technology:Rochester Medical Announces First Quarter 2012 Earnings Conference Call, Wednesday, January 25, 2012 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 3
(Date:7/5/2015)... ... 2015 , ... Security Life Insurance Company of America, a ... of PrimeStar Individual Dental Insurance. Beginning now, enhancements include the expansion of our ... (MAC) and usual, customary and reasonable (UCR). , Whether consumers are looking ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women’s Excellence in Wellness, ... Lake Orion location. The special consists of 2 months of unlimited classes for just ... Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... ... 2015 , ... Chronic Neck Pain. Neck pain is no small ... the neck. Another 19% suffer from head, migraine, or facial pain, in some cases ... of American workers must deal with neck pain. Strategies for mitigating neck ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon ... 2nd creating a buzz of media attention. In an effort to spread the ... Tiffany Hendricks. , "These days many people are feeling overwhelmed by stress and ...
(Date:7/3/2015)... ... , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod ... . To be held from March 4th - 6th, the 2016 (a previous announcement ... Dallas. , Designed to take participants from the basic training and fundamentals of nasal ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... smoking greatly increases the risk that a blood vessel ... called an aneurysm which could be life-threatening if ... Stroke Association,s International Stroke Conference 2010. Researchers reported on ... project, a multinational collaboration funded by the National Institutes ...
... , , ... ... , , ... ...
... first one, number of teeth in first year , FRIDAY, ... in the first year of life have been identified by ... of 6,000 people in Finland and Britain who took part ... until adulthood. The scientists pinpointed five genes associated with the ...
... ... allows point-of-care workers to improve workflow and patient care. , ... (PRWEB) February 26, 2010 ... partnership with Voalt , a leading developer of innovative point-of-care communications software ...
... ... patients and asbestos exposure victims who are interested in learning more about clinical trials ... ... provide comprehensive resources for mesothelioma patients and their loved ones, including information about ...
... ... the public to spend two moonlit evenings basking in blissful meditations and looking at ... ... opportunity to explore life,s most fascinating questions at a most unexpected place, Tampa,s USF ...
Cached Medicine News:Health News:Smoking significantly increases risk of aneurysm in people with certain genes 2Health News:Smoking significantly increases risk of aneurysm in people with certain genes 3Health News:Landauer, Inc. Declares Regular Cash Dividend 2Health News:Genes Behind Tooth Development Discovered 2Health News:Connexall Announces Partnership with Voalt 2Health News:Connexall Announces Partnership with Voalt 3Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 2Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 3Health News:Explore, Love, Happiness, Life Purpose, and Destiny with World Renowned Yogi and Mystic, Sadhguru 2
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: